PHARMAPULSE
The computed 12-month bankruptcy probability of PHARMAPULSE is 0.5% (low). The 2024 annual accounts show equity of €4k and a net result of €3k. Its solvency ranks better than 20% of 413 sector peers (fiscal year 2024). The company has been active since 2024 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €4k |
| Net result | €3k |
| Staff (FTE) | 0.6 |
| Better than sector | 20% |
Mixed profile: strong on profitability, weaker on solvency.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Unlock the full score breakdown, per-year score history and the indicative credit limit with Plus.
See plans →| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 10.1% | 54.7% | |
| Net result | €3k | €19k | |
| Equity | €4k | €45k | |
| Gross operating margin | €49k | €43k | |
| Staff costs | €45k | €67k |
| Fiscal year | 2024 |
|---|---|
| Revenue | - |
| EBITDA | - |
| Net profit | €3k |
| Cash flow | - |
| Staff costs | €45k |
| Income taxes | €944 |
| Dividends | - |
| Total assets | €41k |
| Equity | €4k |
| Debt | €37k |
| of which ≤ 1y | €37k |
| of which > 1y | - |
| Working capital | €4k |
| Employees (FTE) | 0.6 |
| 2024 | |
|---|---|
| Current ratio | 1.11 |
| Quick ratio | 1.11 |
| Working capital ratio | 10.1% |
| Solvency | 10.1% |
| Debt / equity | 8.89 |
| Long-term debt ratio | - |
| Interest coverage | - |
| Gross margin | - |
| Net margin | - |
| ROA | 7.7% |
| ROE | 75.7% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
| Line item | Code | 2024 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €41k |
| Current assets | 29/58 | €41k |
| Amounts receivable within one year | 40/41 | €31k |
| Cash & bank | 54/58 | €9k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €41k |
| Equity | 10/15 | €4k |
| Contributions / capital | 10/11 | €1k |
| Accumulated profits (losses) | 14 | €3k |
| Amounts payable | 17/49 | €37k |
| Amounts payable within one year | 42/48 | €37k |
| Trade debts payable within one year | 44 | €8k |
| Income statement | ||
| Gross operating margin | 9900 | €49k |
| Operating result | 9901 | €4k |
| Financial charges | 65 | €56 |
| Result before taxes | 9903 | €4k |
| Income taxes | 67/77 | €944 |
| Net result for the period | 9904 | €3k |
| Result to be appropriated | 9905 | €3k |
| NACE primary | 78200 |
| Legal form | General partnership(011) |
| Incorporation | 11-04-2024 |
| Status | Active |
| Postal code | 1380 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 25087C0102/00R000 | Wallonia | 2,122 m² | 1 · 109 m² | 6.7 m · 1 fl. |
| 25113C0175/02E000 | Wallonia | 756 m² | 1 · 232 m² | - |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
19-07-2024 Articles of association amended, change of corporate purpose
Technical details
{
"notary": {
"name": null,
"firm_city": null,
"firm_name": null,
"office_city": null,
"is_associated": false
},
"act_meta": {
"language": "fr",
"pub_date": null,
"filing_date": "2000-08-12",
"act_kind_objet": "Modification des statuts"
},
"decision": {
"body": "buitengewone_algemene_vergadering",
"act_date": "2024-06-20",
"unanimous": true
},
"statute_change": {
"kinds": [
"object_change"
],
"scope": "targeted_articles",
"trigger": "other",
"language_after": "fr",
"language_before": "fr"
},
"bedrijfsrevisor": null,
"subject_company": {
"kbo": "1008.309.951",
"name_full_after": "PHARMAPULSE",
"legal_form_after": "SNC",
"name_full_before": "PHARMAPULSE",
"current_zetel_raw": "Rue des Lilas, 1 1470 Genappe",
"legal_form_before": "SNC"
},
"special_mandates": [],
"articles_modified": [
{
"summary": "L\u0027objet social a \u00E9t\u00E9 modifi\u00E9 pour d\u00E9finir l\u0027activit\u00E9 de la soci\u00E9t\u00E9 dans le cadre d\u0027un groupement d\u0027employeurs, consistant \u00E0 mutualiser les besoins de personnel de ses membres.",
"new_text": "La soci\u00E9t\u00E9 a pour objet, dans le cadre d\u0027un groupement d\u0027employeurs au sens du chapitre XI de la loi du 12 ao\u00FBt 2000, de mutualiser les besoins de personnel de ses membres en leur mettant des collaborateurs \u00E0 disposition, selon les conditions et modalit\u00E9s arr\u00EAt\u00E9es dans le r\u00E8glement d\u0027ordre int\u00E9rieur (ROI). Pour r\u00E9aliser ses objectifs, la soci\u00E9t\u00E9 peut \u00EAtre propri\u00E9taire et poss\u00E9der ou d\u00E9tenir tout b",
"change_kind": "amended",
"article_title": "Objet social",
"article_number": "3"
}
],
"governance_change": null,
"publication_proxy": {
"kind": "none",
"org_kbo": null,
"org_name": null,
"person_name": null,
"org_rep_person_name": null
},
"co_filed_documents": [],
"shareholder_rights": null,
"voorwerp_change_summary": "L\u0027objet social de la soci\u00E9t\u00E9 a \u00E9t\u00E9 modifi\u00E9 pour d\u00E9finir son activit\u00E9 dans le cadre d\u0027un groupement d\u0027employeurs, consistant \u00E0 mutualiser les besoins de personnel de ses membres.",
"capital_structure_change": null,
"coordinated_text_lineage": null
}Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameFR | PHARMAPULSE |